Current Report Filing (8-k)
December 19 2017 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December 18, 2017
Enumeral
Biomedical Holdings, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-55415
|
99-0376434
|
(State or Other Jurisdiction
|
(Commission File
|
(I.R.S. Employer
|
of Incorporation)
|
Number)
|
Identification Number)
|
200
CambridgePark Drive, Suite 2000
|
|
|
Cambridge, Massachusetts
|
|
02140
|
(Address of Principal
Executive Offices)
|
|
(Zip Code)
|
(617)
945-9146
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01
|
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On
December 18, 2017, Enumeral Biomedical Holdings, Inc. (the “Company”) received a notice (the “December Notice”)
from OTC Markets Group stating that the Company would be moved from OTCQB to OTC Pink Current Information before the next market
open. The December Notice stated that OTC Markets Group had previously provided the Company with a 90 day grace period to cure
the Company’s bid price deficiency, which had now expired.
As
previously reported, OTC Markets Group had notified the Company in a September 19, 2017 Bid Price Deficiency Notice (the “September
Notice”) that the Company’s bid price had closed below $0.01 for more than 30 consecutive calendar days and no longer
met the Standards for Continued Eligibility for OTCQB as per the OTCQB Standards Section 2.3(2). The September Notice stated that
pursuant to Section 4.1 of the OTCQB Standards, the Company was granted a cure period of 90 calendar days during which the minimum
closing bid price for the Company’s common stock must be $0.01 or greater for ten consecutive trading days in order to continue
trading on the OTCQB marketplace.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ENUMERAL BIOMEDICAL HOLDINGS, INC.
|
|
|
|
|
Dated: December 19, 2017
|
By:
|
/s/ Kevin G. Sarney
|
|
|
Name:
|
Kevin G. Sarney
|
|
|
Title:
|
Interim Chief Executive Officer and President, Vice President of Finance, Chief Accounting Officer and Treasurer
|